)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Imunon (IMNN) investor relations material
Imunon Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary5 Aug, 2025
Executive summary
Phase III OVATION 3 trial for IMNN-001 in advanced ovarian cancer launched, with first patient dosed in July 2025 and 20 sites targeted by year-end.
Phase II OVATION II data showed a 13-month median overall survival benefit and all patients in the experimental arm remained progression-free during treatment.
Multiple presentations at major oncology conferences and peer-reviewed publications validated clinical promise and generated global investigator interest.
PlaCCine DNA vaccine platform showed durable antibody response in Phase 1 COVID-19 trial; program deprioritized for partnering.
Company is focused on funding pivotal trials through partnerships and equity, while minimizing shareholder dilution and maintaining NASDAQ compliance.
Financial highlights
Cash and cash equivalents were $4.7M as of 06/30/2025; an additional $3M raised post-quarter via warrant exercises and ATM sales.
R&D expenses for Q2 2025 were $1.2M, down from $2.8M year-over-year; G&A expenses were $1.5M, down from $2.2M.
Net loss for Q2 2025 was $2.7M ($2.15/share), improved from $4.8M ($7.64/share) in Q2 2024; H1 2025 net loss was $6.8M ($6.08/share), down from $9.7M ($15.51/share) in H1 2024.
Operating expenses for Q2 2025 were $2.8M, a 45% decrease year-over-year; H1 2025 operating expenses were $6.9M, down 31% year-over-year.
Net cash used in operations for H1 2025 was $5.8M, down from $10.4M in H1 2024.
Outlook and guidance
OVATION 3 trial aims for 250 HRD-positive patients initially, with potential expansion to 500 all-comers, both powered for FDA approval.
Sufficient capital resources to fund planned operations into Q4 2025; ongoing efforts to secure non-dilutive funding and strategic partnerships.
Company expects stable expenses as trial enrollment ramps, with cost controls and manufacturing investments already made.
Targeting 20 clinical sites open by year-end, funding dependent.
No revenue expected from product sales in the next several years; continued focus on advancing clinical programs and seeking collaborations.
OVATION 3 trial: How many sites are planned by year-end?
Explain the rationale behind the stock dividend.
When will IMUNON need additional capital?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Imunon earnings date
Q3 20256 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Imunon Inc. is a clinical-stage biotechnology company focused on the development of innovative therapies for oncology and infectious diseases. The company utilizes its proprietary ThermoDox platform, which combines heat-activated liposomal drug delivery with targeted chemotherapy to enhance treatment effectiveness. Imunon also engages in the development of DNA-based vaccines and immunotherapies aimed at improving patient outcomes. The company is headquartered in Lawrenceville, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage